AbCellera Biologics annual stock-based compensation
2019
2020
2021
2022
2023
2024
2025
AbCellera Biologics Stock-Based Compensation Growth & History (ABCL)
AbCellera Biologics's stock-based compensation was $55.8M for fiscal 2025.
View full AbCellera Biologics company overviewAbCellera Biologics annual stock-based compensation history
| Fiscal year | Period ended | Stock-based compensation | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $55.8M | −$11.8M | −17.44% |
| 2024 | 2024-12-31 | $67.6M | $3.4M | +5.29% |
| 2023 | 2023-12-31 | $64.2M | $14.7M | +29.71% |
| 2022 | 2022-12-31 | $49.5M | $18.8M | +61.46% |
| 2021 | 2021-12-31 | $30.6M | $22.2M | +264.96% |
| 2020 | 2020-12-31 | $8.4M | $7.5M | +843.48% |
| 2019 | 2019-12-31 | $890,000 | — | — |
AbCellera Biologics quarterly stock-based compensation
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Stock-based compensation | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $12.3M | −$1.9M | −13.52% |
| Q1 2026 | 2026-03-31 | $12.0M | −$2.8M | −18.75% |
| Q4 2025 | 2025-12-31 | $12.9M | −$2.3M | −15.25% |
| Q3 2025 | 2025-09-30 | $13.9M | −$3.3M | −19.05% |
| Q2 2025 | 2025-06-30 | $14.2M | −$3.6M | −20.10% |
| Q1 2025 | 2025-03-31 | $14.8M | −$2.6M | −15.07% |
| Q4 2024 | 2024-12-31 | $15.2M | −$1.2M | −7.43% |
| Q3 2024 | 2024-09-30 | $17.2M | $1.3M | +8.21% |
| Q2 2024 | 2024-06-30 | $17.8M | $1.4M | +8.43% |
| Q1 2024 | 2024-03-31 | $17.4M | $1.9M | +12.50% |
| Q4 2023 | 2023-12-31 | $16.4M | $3.1M | +23.46% |
| Q3 2023 | 2023-09-30 | $15.9M | $4.1M | +34.95% |
| Q2 2023 | 2023-06-30 | $16.4M | $4.3M | +35.38% |
| Q1 2023 | 2023-03-31 | $15.5M | $3.2M | +25.90% |
| Q4 2022 | 2022-12-31 | $13.3M | $4.3M | +47.41% |
| Q3 2022 | 2022-09-30 | $11.8M | $4.0M | +52.49% |
| Q2 2022 | 2022-06-30 | $12.1M | $3.6M | +42.96% |
| Q1 2022 | 2022-03-31 | $12.3M | $6.9M | +126.48% |
| Q4 2021 | 2021-12-31 | $9.0M | $4.4M | +95.54% |
| Q3 2021 | 2021-09-30 | $7.7M | $5.8M | +298.96% |
| Q2 2021 | 2021-06-30 | $8.5M | $7.9M | +1298.18% |
| Q1 2021 | 2021-03-31 | $5.4M | $4.2M | +338.72% |
| Q4 2020 | 2020-12-31 | $4.6M | — | — |
| Q3 2020 | 2020-09-30 | $1.9M | — | — |
| Q2 2020 | 2020-06-30 | $606,000 | — | — |
| Q1 2020 | 2020-03-31 | $1.2M | — | — |
AbCellera Biologics stock-based compensation trends
Over the last five fiscal years, AbCellera Biologics's stock-based compensation increased from $8.4M to $55.8M, a change of $47.4M. The latest reported quarter, Q2 2026, shows $12.3M.
About the metric
What stock-based compensation means
Stock-based compensation is the expense associated with equity awards such as restricted stock and employee options. It is a non-cash expense when recognized, but it can dilute existing shareholders unless offset by share repurchases.
Calculation and source
SEC-reported stock-based compensation
TickerStat standardizes share-based compensation reported in company SEC filings. The history shows recognized compensation expense or its cash-flow-statement adjustment, not the grant-date value of new awards or a forecast of future dilution. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review AbCellera Biologics source filings ↗